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Abstract
Hereditary inclusion body myopathy (HIBM) is an adult onset, slowly progressive distal and proximal myopathy.
Although the causing gene, GNE, encodes for a key enzyme in the biosynthesis of sialic acid, its primary function in
HIBM remains unknown. The goal of this study was to unravel new clues on the biological pathways leading to HIBM
by proteomic comparison. Muscle cultures and biopsies were analyzed by two dimensional gel electrophoresis (2-DE)
and the same biopsy extracts by isobaric tag for relative and absolute quantitation (iTRAQ). Proteins that were
differentially expressed in all HIBM specimens versus all controls in each analysis were identified by mass spectro-
metry. The muscle cultures 2-DE analysis yielded 41 such proteins, while the biopsies 2-DE analysis showed
26 differentially expressed proteins. Out of the 400 proteins identified in biopsies by iTRAQ, 41 showed altered
expression. In spite of the different nature of specimens (muscle primary cultures versus muscle biopsies) and of
the different methods applied (2D gels versus iTRAQ) the differentially expressed proteins identified in each of the
three analyses where related mainly to the same pathways, ubiquitination, stress response and mitochondrial processes,
but the most robust cluster (30%) was assigned to cytoskeleton and sarcomere organization. Taken together, these
findings indicate a possible novel function of GNE in the muscle filamentous apparatus that could be involved in the
pathogenesis of HIBM.
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Introduction
Hereditary inclusion body myopathy (HIBM or IBM2; OMIM
600737) constitutes a rare autosomal recessive neuromuscular
disorder characterized by slowly progressive distal and proximal
muscleweaknessofthe limbs[1].HIBMismostcommon amongthe
Jewish-Persian community with a prevalence of 1:1500. However, in
Japan there is an important cluster of patients with the same
disorder, known there as distal myopathy with rimmed vacuoles
(DMRV) and affected single non Jewish families from different
origins can be found worldwide. The initial symptom, altered gait,
appearsusuallyduringthethirddecadeoflifeduetofootdorsiflexion
muscles involvement.Later inthecourse ofthediseaseother muscles
are involved, however for unknown reason the quadriceps is
relatively spared. A typical HIBM muscle pathology includes
cytoplasmic rimmed vacuoles and cytoplasmic or nuclear 14 to
18nm tubulofilamentous inclusions that give the disease its name [2].
The molecular basis of the disease was found to be mutations in
GNE, the gene encoding the enzyme UDP-N-acetylglucosamine 2-
epimerase/N acetylmannosamine kinase (UDP-Glc-NAc 2-epimer-
ase/ManNAc kinase) [3]. In Jews of Persian descent, a single
homozygous missense mutation was identified, however in patients
from non Jewish families of various origins, different mutations,
mostly missense compound heterozygotes, were found in all exons of
GNE, in both domains of the protein [4,5]. GNE is the rate-limiting
enzyme in the biosynthetic pathway of sialic acid and catalyzes the
first two steps by each one of the two distinct functional domains [6].
Sialic acids are the most abundant terminal monosaccharides on
glycoproteins and glycolipids in eukaryotic cells. They comprise a
family of more than 50 naturally occurring carboxylated amino
sugars with a scaffold of nine carbon atoms [7]. Sialic acids influence
adhesion processes which play an important role in many cellular
functions, such as cell migration, transformation of tissues,
inflammation, wound healing and metastasis [8–10]. In spite of
extensive experimental work in the last decade, the contribution of
GNE mutations to the HIBM phenotype remains unresolved and the
issue of hyposialylation in HIBM muscles is still controversial. The
goal of this study was to compare the proteomes of HIBM primary
muscle cultures and biopsies to controls by 2 dimensional
polyacrylamide gel electrophoresis (2-D PAGE) and isobaric tag
for relative and absolute quantitation (iTRAQ) analyses in an
attempt to identify potential proteins that may be involved in the
HIBMphenotypeandthereforeunravelbiologicalpathwaysaffected
by mutations in GNE.
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Ethics Statement
Muscle samples were collected with the informed consent of the
participants. These studies were approved by the Institutional
Review Board of Edith Wolfson Medical Center, Holon, Israel.
Muscle biopsies
All muscle biopsies were collected and immediately frozen in
liquid nitrogen until used for protein extraction. An additional
muscle specimen was placed in PBS and used for the establishment
of primary myoblast culture for some individuals (Table 1). The
normal muscle specimens were collected from consenting indi-
viduals who had undergone either muscle biopsy which eventually
was diagnosed as normal or orthopedic surgery. HIBM patients
were clinically and genetically diagnosed, most of them of Jewish
Persian descent carrying the homozygous M712T mutation in
GNE, unless otherwise noted. Since high variability can be found
in many parameters among muscle and muscle cultures from
different individuals, we matched appropriate control sample to
each HIBM sample, by age (all young adults), gender and muscle
type, as closely as possible (Tables 1, 2). Biopsies of patients were
taken from clinically affected muscles.
Analysis of muscle cultures by 2-D PAGE
All chemicals were obtained from SIGMA (St. Louis, MO,
USA). DME medium, Ham’s F-10 medium, FBS, horse serum,
PBS, Trypsin, Penicillin, Streptomycin and Glutamine were
obtained from Biological Industries (Beit Haemek, Israel). Fresh
biopsies were processed as previously described [11]. To initiate
differentiation, growth medium was replaced by DME medium
containing 2% HS, referred as differentiation medium. Myoblasts
were differentiated for at least 5 days. Sialic acid uptake was
avoided by growing the cells in serum-free medium (DCCM,
Biological Industries) for 2–3 days prior to harvesting. Differential
cells were harvested at 70% confluency by 2 mM EDTA in order
to avoid digestion of membrane proteins by trypsin. Cell pellets
were resuspended in 0.5 mL lysis buffer (10 mM Tris-HCl,
pH 7.4, 1 mM EDTA and 1.4 mM PMSF) and disrupted by
sonication. Cell debris and protein aggregates were removed by
centrifugation at 200006g for 30 min at 4uC. The protein
concentration was determined using the Bradford method (Sigma)
with the Protein Assays kit (Bio-Rad, CA, USA). The supernatants
containing the proteins were lyophilized and sent to the Maiman
Institute for Proteome Research at Tel Aviv University, Israel.
Isoelectric focusing was performed with IPG-strips, 18 cm, pH 4–
7 (Amersham Biosciences, NJ, USA). Samples were loaded by
rehydration for 24 h in a solution containing 8 M urea, 2 M
thiourea, 1% w/v CHAPS, 20 mM DTT and 0.5% v/v
Pharmalyte 4–7. The isoelectric focusing was performed with
the MultiphorII unit (Amersham Biosciences) employing the
following voltage profiles [12]: linear increase from 0 to 500 V
for 2500 Vh, 500 V for 2500 Vh, linear increase from 500 to
3500 V for 10000 Vh and a final phase of 3500 V for 35000 Vh.
After consecutive equilibration of the gels in solutions containing
DTT and iodoacetamide as suggested by Go ¨rg et al. [13] the
separation in the second dimension was performed in polyacryl-
amide 20620 cm gels of 12.5% on a 2-DE system (Genomic
Solutions, Chelmsford, MA, USA). Analytical and preparative gels
were loaded with 350 mg of crude protein extract and the gels were
stained with colloidal Coomassie.
Peptide mass sequencing and protein identification
Protein identification was accomplished according to established
protocols [14]. Briefly, protein spots were excised from Coomassie
Blue stained gels, the gel pieces were washed in a 200 mM
NH4HCO3-50% acetonitril solution for 30 minutes at 37uC. The
solution was discarded and the gels were dried in a speed vac for
30 minutes. The gels were rehydrated in a solution of 20 mg/mL
trypsin (Promega, Madison, WI, USA) and the proteins were
digested for 16 h at 37uC. Peptides were extracted from the gel by
diffusion in 10% acetonitril and desalted on micro-columns
containing a 1:1 mixture of POROS R2–50 and Poros Oligo
R3 (Perseptive BioSystems). The peptides were eluted with 70%
(v/v) acetonitril-double distilled water saturated with a-cyano-3-
hydroxycinnamic acid onto a sample plate for MALDI-MS.
Peptide masses were determined in the positive ion reflector mode
in a Voyager-DE STR mass spectrometer (Applied Biosystems,
CA, USA) with internal calibration. Peptide mass fingerprints were
compared to databases using the MS-Fit program (http://
prospector.ucsf.edu). The searches took into consideration oxida-
tion of methionine, pyroglutamic acid formation at the N-terminal
glutamine and modification of cysteine by carbamidomethylation
or acrylamide, as well as partial cleavage leaving one internal
cleavage site [14].
Western analysis
For Western blot analysis, lysates equivalent to 25 mg of total
protein were fractionated by denaturing sodium dodecyl sulfate
7.5% polyacrylamide gel electrophoresis and transferred to
nitrocellulose (Schleicher and Schuell, Dassel, Germany) by
standard electroblotting techniques. After 1 h blocking in 3%
BSA/PBS-Tween (0.01%), membrane was washed 3 times with
PBS-Tween (0.01%) and incubated for 1 h with primary antibody
diluted in blocking buffer. To validate 2-D PAGE results the
Table 1. Characteristics of muscle cultures used in 2-DE
analysis.
Status Muscle specimen Age (years) Gender Culture
a)
HIBM Deltoid 26 Male MS-17
1
HIBM Deltoid 29 Male MS-20
2
HIBM Gastrocnemius 30 Male MS-312
3
Control Deltoid 27 Male N-17
1
Control Deltoid 33 Male N-20
2
Control Deltoid 46 Male MS-35
3
a)Matched pairs are labeled with the same number: 1, 2 or 3.
doi:10.1371/journal.pone.0016334.t001
Table 2. Characteristics of Muscle biopsies used for 2-DE and
iTRAQ analyses.
Status Muscle specimen Age (years) Gender Biopsy
a)
HIBM Deltoid 48 Male B-147
1
HIBM Tibialis anterior 22 Female B-220
2
HIBM Deltoid 35 Female B-171
3
Control Deltoid 48 Male B-270
1
Control Deltoid 22 Male B-181
2
Control Deltoid 32 Male B-190
3
a)Matched pairs are labeled with the same number: 1, 2 or 3.
doi:10.1371/journal.pone.0016334.t002
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T1 (1:1000; Chemicon, CA, USA), mouse monoclonal anti VCP
(1:300; BD Biosciences, CA, USA), mouse monoclonal anti
vimentin (1:1000; Sigma), mouse monoclonal anti N-CAM (1mg/
ml; Invitrogen, CA, USA), goat polyclonal anti HSP 27 (M-20) and
rabbit polyclonal anti lamin a/c (1:500; Santa Cruz Biotechnology,
CA, USA). Detection was performed by enhanced chemilumines-
cence after incubation with HRP-conjugated antibodies (1:80000;
Jackson ImmunoResearch, West Grove, PA, USA).
Analysis of biopsy specimens by 2-D PAGE
Total protein was extracted from biopsies by TRIzol
TM (Sigma)
according to manufacturer protocol. 50mg of each protein extract
were transferred to a new tube and used later for iTRAQ analysis
and the remained extract was prepared for the 2-D PAGE
analysis. Both analyses were done at the Smoler Proteomics
Center at the Technion, Haifa. The remaining protein sample was
resuspended in a sample solubilization buffer containing 7 M urea,
2 M thiourea, 2% w/v CHAPS, 65 mM DTT, 0.3% v/v
ampholyte 3–10, 0.1% v/v ampholyte 6–11, 0.1% v/v ampholyte
4–7 and 5 mL Bromo-Phenol-Blue (BPB). Protein amount was
quantified using a modified Bradford analysis. The IPG strip (3–11
NL, Immobiline DryStrip 18 cm, Amersham Biosciences) was
rehydrated with 400 mg protein in 350 mL of the protein sample.
The rehydration was performed for 1 h with no voltage followed
by 12–16 h at 50 mV. Isoelectric focusing was then performed for
1 h at 200 V, 1 h at 500 V, 1 h at 1000 V, 30 min linear increase
to 8000 V and up to 12 h at 8000 V to the final value of
95000 VH. Following isoelectric focusing each strip was equili-
brated in 100 mg DTT in 10 mL of equilibration buffer
containing 6 M urea, 30% w/v glycerol and 2% SDS in 0.05 M
Tris-HCl buffer (1.5 M Tris-HCl and 0.4% w/v SDS), pH 8.8
with 10 mL BPB for 20 min. A second equilibration step was
performed for 20 min with 400 mg IAA in 10 mL of the above
equilibration buffer. After equilibration, each sample of the
immobilized pH gradient strips was loaded onto Tris-SDS gel
7–15%, 20620.5 cm along with ‘‘Dual Color’’ molecular weight
marker (Bio-Rad, CA, USA). The proteins entered the gel in
100 V for ,5 h and ran over night at 30 V. Each Gel sample was
stained with Imperial protein staining solution (Pierce, IL, USA).
Images of the gels were acquired using Microtek’s ScanMaker
9800XL and analyzed using PDQUEST 7.3.1 software (Bio-Rad).
In gel proteolysis and mass spectrometry analysis
Selected differential spots were cut from the gel. The proteins in
the gel were trypsinized (Promega) at a 1:100 enzyme to substrate
ratio. The resulting tryptic peptides were resolved by reverse-phase
chromatography on 0.0756200 mm fused silica capillaries (J&W;
Agilent technologies, Santa Clara, CA, USA) packed with Reprosil
reversed phase material (Dr Maisch GmbH, Germany). The
peptides were eluted with linear 65 minutes gradients of 5 to 45%
and 15 minutes at 95% acetonitrile with 0.1% formic acid in water
at flow rates of 0.25 mL/min. Mass spectrometry was performed
by an ion-trap mass spectrometer (Orbitrap; Thermo Fisher
Scientific, Waltham, MA, USA) in a positive mode using
repetitively full MS scan followed by collision induces dissociation
(CID) of the 7 most dominant ion selected from the first MS scan.
The mass spectrometry data was clustered and analyzed by using
the Sequest software [15] and Pep-Miner [16] searching engine
against the Human part of the NR-NCBI database.
Analysis of biopsy specimens by iTRAQ
The remaining 50 mg of the above TRIzol
TM protein extracts
were resuspended in 8 M Urea in 100 mM Ammonium
bicarbonate and were reduced (10 mM DTT) and modified with
40 mM iodoacetamide. The sample was diluted to 2 M urea in
water and the proteins were trypsinized with 2 mg bovine trypsin
at 37uC overnight. The resulting peptides were cleaned on
disposable Silica C18 tip (Harvard) and resuspended in 100 mM
Hepes (pH 7.3). The iTRAQ
TM Reagent (Applied biosystems) was
brought to room temperature and mixed with ethanol (30:70).
After vortexing and spinning, each one of the reagents was
transferred to one sample tube. The tubes were incubated at room
temperature for 1 h. All four iTRAQ
TM reagent labeled samples
were combined, cleaned on C18 and resuspended in 0.1% formic
acid. Sixty micrograms of the combined labeled peptides were
separated in an on-line two dimensional chromatography
experiment (MuDPiT). First the peptides were loaded on 15 mm
of BioX-SCX column (LC Packing; Dionex, CA, USA)) and eluted
with 8 salt steps of 0, 40, 100, 150, 200, 300, 500 and 1000 mM
ammonium acetate in 5% ACN and 0.1% acetic acid, pH 3. The
eluted peptides were further resolved by capillary reverse-phase
chromatography (75m ID, 30 cm fused silica capillaries, J&W self-
packed with 3 m Reprosil-Aqua C18). The peptides were eluted
using a 125 min gradient (5% to 40% acetonitrile containing 0.1%
formic acid) followed by a wash step of 95% acetonitrile for
15 min. The flow rate was about 0.2 mL /min and the peptides
were analyzed by LC-MS/MS on QTOF-Premier mass spec-
trometer (Waters, Milford, MA, USA). Mass spectrometry was
performed in a positive mode using repetitively full MS scan
followed by collision induces dissociation (CID) of the 3 most
dominant ion selected from the first MS scan. The mass
spectrometry data was clustered analyzed and compared using
the Pep-Miner searching the human, mouse, rat and bovine part
of the NR-NCBI. The identification was done by Sequest search
engine, and the quantitation was done it the Libra module from
the Trans Proteomics Pipeline [17], comparing the intensity of
114, 115, 116 and 117 ions in each MS/MS spectrum. Each
sample was compared to the standard sample B-190 of the same
run.
Results and Discussion
Primary muscle cultures 2-D PAGE
HIBM is a late onset disease that appears after the muscle tissue
in the organism is fully differentiated. Therefore, we conducted
proteomic analysis in differentiated cultured myotubes. To our
experience each culture has its own differentiation rate, which is
not correlated with the disease status of the donor. However,
analysis by using anti-MyHC (myosin heavy chain) antibody
indicated that the muscle cultures we established in our laboratory
are fully differentiated after 5 days in differentiation medium [18].
The matched pairs’ characteristics of 3 HIBM and 3 controls
primary muscle cultures are presented in Table 1. All the cultures
were from deltoid origin except one affected that was gastrocne-
mius; all samples were clinically affected. In HIBM, deltoid muscle
also becomes affected as the disease progresses and the disease
pathophysiology is similar in all muscles once they become
affected. Although age did not match perfectly between affected
patient and control for the last pair (30 versus 46), we think that
this age range as well as the entire age range analyzed in this study
(Table 1 and Table 2- age range 22–49) still represents subjects at
the same stage of life and of muscle biology (young adults). Two of
the patients analyzed are of Jewish Persian descent and harbor the
founder homozygous mutation at the kinase domain, M712T, and
one Persian non Jewish patient (MS-312) carries a homozygous
epimerase mutation, V367I [19]. Since muscle culture MS-312
has a different mutation than the other 2 HIBM samples, its
The Proteomic Profile of HIBM
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proteomic profile and minimize any mutation specific differences.
The cultures were differentiated for 5 days and then incubated for
2–3 more days in free-serum medium in order to prevent sialic
acid absorption by the cells. 2-D PAGE of total protein extracts for
each sample was performed and achieved a consistent general
proteomic pattern on 20 cm gels of pH 4.0–7.0 (Fig. 1A–B). Each
HIBM muscle culture proteomic map was compared to its
matched control to generate a master proteomic map by
PDQUEST 7.3.1 software (Fig. 1C).
In order to focus on disease related proteins, only spots that
were found to be differentially expressed (student’s test; p,0.05) by
computerized analysis in all the 3 HIBM samples versus all 3
controls were identified by peptide mass fingerprinting. Each
differentially expressed spot was extracted and identified from one
HIBM and one control gel to verify that the correct protein spots
were compared. The analysis showed 65 differentially expressed
spots and 41 proteins were identified; 12 proteins were found to be
up-regulated in HIBM myotubes and 29 were down-regulated
(Table 3). Data analysis with IPA (Ingenuity Systems) and DAVID
(NIH) softwares showed that 31.7% of the differentially expressed
proteins are related to cytoskeleton and sarcomere organization
(e.g., MYL4, MLRS, & TNNT1). Other functional groups were
assigned to ubiquitination (9.7%), glycolysis (7.3%) mitochondrial
processes (7.3%) and stress response (4.8%) (Fig. S1). The
differential expression ratios were higher than 2 fold for most
proteins and western analyses were performed by using selected
antibodies to verify the 2-D PAGE proteomic data for few proteins
(Fig. S2). The level of troponin-1 and vimentin detected by western
blot was in line with the 2-DE analysis results; (vimentin expression
was higher in patient samples; troponin-T1 expression was higher
in controls); however we could detect only very slight changes
between the 2 sample groups in the level of expression of lamin A
or heat shock protein 27 in this assay. One explanation could be
that the antibodies used detect a different isoform of the protein.
Alternatively, several isoforms can be detected, while only one
specific isoform was identified from the gel spot. As control
proteins we assayed the expression of NCAM, which is a highly
polysialylated protein expressed in proliferating satellite cells [11]
and VCP, a protein found to be mutated in a myopathy with high
similarities to HIBM, inclusion body myopathy associated with
Paget disease of bone and frontotemporal dementia (IBMPFD;
OMIM 167320) [20]. As expected, no expression differences could
be detected in these proteins between the two muscle culture types.
To note, in spite of the differences seen in the expression of
several sarcomeric proteins between HIBM and control cell
cultures that could anticipate that HIBM derived cells would
present some defect of development, no differences could be
detected in these cultures in our previous studies [18] in terms of
morphology, proliferation rate or differentiation processes, except
for their response to apoptosis through the AKT pathway.
2-D PAGE analysis of muscle specimens
For 2D PAGE analysis, skeletal muscle specimens were
obtained from HIBM patients who harbored the founder
homozygous mutation M712T (Table 2). Five of the 6 samples
(3 pairs of HIBM/controls) were deltoid muscle, one affected was
tibialis anterior. As seen in Fig. S3, all 3 affected muscles (2
Figure 1. 2-DE representative proteomic maps (pH 4.0–7.0) of muscle cultures. A. MS-35 control deltoid muscle; B. MS-312 HIBM deltoid
muscle; C. Representative virtual overlay map of controls and HIBM gels; protein expression of control (blue), HIBM (orange) and overlapped
expression (black). Only unique (blue or orange) spots were analyzed further.
doi:10.1371/journal.pone.0016334.g001
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Ref. spot
Description and
gene name
Swiss-Prot
name/ID
HIBM/
Control
Fold change
Peptides
m/o
Sequence
coverage
(%) p-value Mr (Da)
a) pI
a)
Possible
function
ID633952 Myosin light chain 2;
myosin regulatory
light chain 2
MLRS/Q96A32 0.28 5/64 7 2.5E-05 19014.7 4.91 Cytoskeleton
organization
ID633701 Atrial/embryonic alkali
myosin light chain
MYL4/P12829 0.44 21/103 49 0.030 21433.41 4.98 Cytoskeleton
organization
ID633133 Tubulin alpha 6 TBA1C/Q9BQE3 0.46 6/84 21 0.010 49895.6 4.96 Cytoskeleton
organization
ID633428 Actin alpha cardiac
muscle precursor
ACTC/P68032 2.96 12/83 26 0.031 42019.2 5.23 Cytoskeleton
organization
ID633599 Tropomyosin 3 TPM3/P06753 2.51 24/95 39 0.002 32818.79 4.68 Cytoskeleton
organization,
cell motility
ID633361 Vimentin VIME/P08670 2.03 16/76 44 0.016 53686.0 5.06 Cytoskeleton
organization,
cell motility
ID633085 Radixin RADI/P35241 0.34 6/64 12 0.048 68564.2 6.03 Cytoskeleton
organization,
actin binding
ID633703 Actin, gamma 2
propeptide
ACTH/P63267 2.37 8/84 9 0.020 41877.1 5.31 Cytoskeleton
organization,
actin signaling
ID633154 WD repeat-containing
protein 1 isoform 2
WDR1/O75083 0.28 5/61 7 0.018 58002.6 6.41 Cytoskeleton
organization,
actin assembly
ID633113 Kelch repeat and
BTB (POZ) domain
KBTBA/O60662 0.46 14/75 25 0.010 66791.4 5.49 Muscle contraction
ID633541 Troponin T1 TNNT1/P13805 0.25 8/82 9 0.004 32934.3 5.85 Muscle contraction,
calcium signaling
ID633032 Nexilin NEXN/Q0ZGT2 0.13 2/108 3 0.009 80658.28 5.31 F actin binding,
stress fibers
ID633067 Zyxin ZYX/Q15942 0.26 4/72 12 0.004 61277.7 6.22 Cell adhesion,
a- actinin binding
protein
ID206244 Proteasome 26S
ATPase subunit 5
PRS8/P62195 0.10 6/93 19 0.015 45626.3 7.11 Ubiquitination
pathway
ID633695 Ubiquitin
carboxyl-terminal
esterase L1
UCHL1/P09936 2.18 5/69 28 0.008 24824.5 5.33 Ubiquitination
pathway
ID633442 COP9 signalosome
subunit 4
CSN4/Q9BT78 2.24 7/71 20 0.027 46269.1 5.57 Ubiquitination
pathway
ID633046 Proteasome 26S
non-ATPase
subunit 2
PSMD2/Q13200 0.47 13/87 19 0.039 100200.3 5.08 Ubiquitination
pathway,
proteosome
ID633001 Enolase 3 ENOB/P13929 0.10 5/93 12 0.006 46959.1 7.58 Glycolysis
ID633004 2-oxoglutarate
dehydrogenase
ODO1/Q02218 0.20 12/59 10 0.001 113478.1 6.62 Glycolysis
ID633347 Enolase 2 ENOG/P09104 2.29 4/76 5 0.015 47268.8 4.91 Glycolysis
ID633294 ATP synthase ATPA/P25705 0.15 10/80 26 0.024 59750.9 9.16 Oxidative
phosphorylation
ID633089 NADH
dehydrogenase
NDUS1/P28331 0.26 11/89 23 0.004 79468.0 5.89 Oxidative
phosphorylation
ID633251 Aldehyde
dehydrogenase 1A1
AL1A1/P00352 0.22 12/96 25 0.010 54862.1 6.30 Electron transport,
alcohol metabolism
ID633422 Reticulocalbin 1 RCN1/Q15293 2.29 7/61 25 0.041 38890.2 4.86 Calcium binding
ID633408 Reticulocalbin 3 RCN3/Q96D15 3.25 8/92 41 0.010 37493.2 4.74 Calcium binding, ER
ID633167 Stress-induced-
phosphoprotein 1
STIP1/P31948 0.46 9/81 13 0.003 62639.6 6.40 Stress response
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pathology, at a similar stage.
2-DE proteomic maps of three HIBM biopsies and their
matched controls were generated using 20 cm gels over a pH
range of 3.0–11.0. Each HIBM biopsy was compared to its
matched control by PDQUEST 7.3.1 software (Fig. 2) and only
spots significantly differentially expressed (student’s test; p,0.05) in
all 3 HIBM samples versus all 3 controls were identified by MS/
MS spectra. Peptides from 34 extracted spots were related to 26
different proteins by using Sequest and Pep-miner softwares with
comparison to the human part of NR-NCBI database (Table 4,
Table S1). When similar proteins were identified at different spots
their altered expression was always in the same direction and
therefore, it is not likely that a certain isoform or post-translational
modification is more abundant than the other in one of the sample
groups. Computerized analysis revealed that the expression of
78% of altered proteins was upregulated in HIBM biopsies and
that, in accordance with the muscle culture results, the main
cluster of differentially expressed proteins was attributed to
cytoskeleton and sarcomere organization functions (46.1%) (e.g.,
MYL3, MYH7, TNNI1 & TNNT1). Other functional groups
of proteins were related mainly to oxidative phosphorylation
(NDUS1, ATPA & QCR1), stress response (HSPB1, HSP7C &
CRYAB) and glycolysis (ODO1, KPYM & K6PF), each of them
representing 13-11.5% of all the identified differential proteins
(Fig. S4).
iTRAQ analysis of muscle specimens
The same biopsies protein extracts that were subjected to 2-D
PAGE above were also relatively quantified by iTRAQ (Table 5).
In addition, in an attempt to determine as precisely as possible
the specificity of the proteome of HIBM versus other clinically,
pathogenically and/or histologically related muscle disorders, we
included in this analysis 4 biopsy samples of Welander distal
myopathy (WDM; OMIM 604454), Tibial muscular dystrophy
(TMD; OMIM 600334) and Distal myopathy type 3 (MPD3;
OMIM 610099) that exhibit closely related features to HIBM
[21–23] (Table 5). In each run four samples were tested including
the control sample B-190 that was used as internal standard.
Each sample’s tryptic peptides were uniquely mass tagged and
mixed with their matched pair sample. The peptides mixture was
then separated in 2D LC-MS/MS and the data was analyzed
with the Pep-Miner software searching against the NR-NCBI
database. About 400 proteins were identified, in each sample,
Ref. spot
Description and
gene name
Swiss-Prot
name/ID
HIBM/
Control
Fold change
Peptides
m/o
Sequence
coverage
(%) p-value Mr (Da)
a) pI
a)
Possible
function
ID633686 Heat shock 27kD
protein 1
HSPB1/P04792 5.42 5/56 25 0.016 22782.6 5.98 Stress response to
unfolded proteins
ID633127 Vesicle
transport-related
protein isoform a
SCFD1/Q8WVM8 0.29 6/72 16 0.003 72380.2 5.89 Vesicle mediated
transport, ER to
Golgi
ID633030 Coatomer protein
complex, subunit
gamma 1
COPG/Q9Y678 0.17 11/73 14 6.9E-05 97718.8 5.32 Vesicle mediated
transport, Golgi to
ER
ID633001 RAN binding protein 5 IPO5/O00410 0.38 6/82 5 0.006 125545.8 4.80 Protein import to
nucleus
ID633133 Nuclear VCP-like NVL/O15381 0.36 6/65 9 0.010 82746.6 6.04 ATP binding
triphosphatase
activity
ID633294 Glutamate
dehydrogenase 1
DHE3/P00367 0.15 7/80 16 0.024 61398.2 7.66 AA metabolism
ID633154 EH-domain
containing 4
EHD4/Q9H223 0.28 9/61 15 0.018 61175.5 6.33 AA metabolism
ID633646 6-phospho-
gluconolactonase
6PGL/O95336 2.13 7/88 41 0.001 27547.0 5.70 Carbohydrate
metabolism
ID633646 Peroxisomal long-chain
acyl-coA thioesterase
ACOT2/P49753 0.10 6/93 15 0.001 53265.9 8.82 Fatty acid
metabolism
ID633236 Dihydropyrimidinase-
like 2
DPYL2/Q16555 3.08 5/97 11 0.019 62294.0 5.95 Cell communication
ID410685 Cyclin-dependent
kinase 3
CDK3/Q00526 0.14 4/71 16 0.008 35045.9 8.86 Cell cycle
ID633149 Protein arginine
methyltransferase 5
isoform a
ANM5/O14744 0.24 11/114 18 0.002 72684.3 5.88 Cell proliferation
ID633341 Lamin A/C LMNA/P02545 0.25 11/54 21 0.017 65135.1 6.40 Apoptosis signaling
ID633127 PMF-1 binding protein PMFBP/Q8TBY8 0.29 10/109 13 0.003 117480.4 5.90 Cell death
ID633341 Protein phosphatase 2
isoform b
2AAB/P30154 0.46 7/75 11 0.017 73585.2 4.96 Cell death
Theoretical pI and Mr values were calculated using the ExPASY tool. m=matched peptides, o=observed peptides.
doi:10.1371/journal.pone.0016334.t003
Table 3. Cont.
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HIBM or control samples. The Wilcoxon signed-rank test
revealed 41 proteins (Table 6, Table S2) that were most
differentially expressed in all 3 HIBM samples versus all 3
controls, however this difference was not statistically significant
(p=0.1090). Comparison of these 41 proteins between the 3
control samples versus all 4 samples of non HIBM myopathies by
Mann-Whitney test showed significant expression differences
(p=0.037) only for four of them: ALBU, TPM2, CASQ1 and
ANKR2. These proteins could represent more common or
downstream pathways for distal myopathies and are probably not
specific solely to the HIBM pathophysiology. Thus, the 37
remaining differential expressed proteins may be considered as
HIBM specific, at least among these distal myopathies.
Functional annotation analyses of these proteins by DAVID
and IPA softwares coincide with the 2-D PAGE findings of both
muscle biopsies and myotubes cultures and show that gene
products differentially expressed in HIBM versus controls are
involved in carbohydrate metabolism (17.0%), mitochondrial
processes (12.1%) and glycolysis (12.1%) but the main cluster
represents again proteins involved in cytoskeleton and sarcomere
organization (29.2%) (Fig. S5). Taken together from the 2-DE
and the iTRAQ analyses, 61 proteins were differentially
expressed and the majority of them showing less than 2 fold
changes. Although only few proteins overlapped in all 3 assays,
overall the largest group of altered proteins in all 3 comparisons
analyses was related to cytoskeleton and sarcomere organization
(Fig. 3).
HIBM proteome in biopsies versus muscle cultures
Most differentially expressed proteins (85%) were overex-
pressed in HIBM biopsies, although the expression ratios were
lower than 2 fold. The low differential ratios obtained from the
biopsies analysis are consistent with our previous GeneChip
HIBM biopsies expression microarrays studies that also demon-
strated less than 2 fold change in most of the differential
transcripts detected [24] and possibly maybe expected in a late
onset slowly progressive disease. In contrast, and in spite of the
fact that no changes were observed in either proliferation,
differentiation or senescence patterns [18] and no organization
aberrations were detected when the cells were grown in 3D
cultures (Mitrani-Rosenbaum et al., unpublished observations),
about 70% of the proteins found to be differentially expressed in
the disease cultured myotubes were downregulated. In addition,
most of the differential proteins ratios in the myotube cultures
were higher than 2 fold. To explain this issue, one should
consider the nature of the samples analyzed: biopsies represent
mature muscle tissue, organized as sarcomeres, and probably
reflect the behavior of the organism in terms of global physiology,
so that the overexpression of many proteins seen in the biopsies
analysis could result from the compensatory mechanisms taking
place in the muscle tissue as a whole, in an attempt to maintain
the tissue organization that confers to muscle its function. In
contrast, muscle cultures components are solely ‘‘isolated’’
satellite cells, and therefore could reflect only the basic and
maybe more primary cellular defects occurring in HIBM, such as
down regulation of many proteins. Even though, the differential
proteins found in the analysis of both muscle cultures and biopsies
were related to the same several functional groups, assigned to
mitochondrial processes, stress response and ubiquitination, the
main cluster being represented by proteins involved in cytoskel-
eton and sarcomere organization. Therefore, as a whole, it seems
reasonable to use HIBM primary muscle cultures as a model to
investigate the fine molecular cascades that lead to the pathology
of the disease. In these studies we have also compared 2
techniques for proteomic analysis, by using the same biopsies
protein extracts in 2-D PAGE and iTRAQ analyses. By both
analyses, the biological pathways unraveled in HIBM pathophys-
iology were the same, although the expression fold figures were
much higher in the 2-DE analysis than in the iTRAQ one, even
Figure 2. 2-DE proteomic maps (pH 3.0–11.0) of A. B-270 control deltoid muscle and B. B-147 HIBM deltoid muscle.
doi:10.1371/journal.pone.0016334.g002
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explanation could be that in a specific 2-DE gel spot which is
quantified, very often more than one protein could be detected,
while in the iTRAQ technique, proteins and peptides are
separated much more efficiently.
Changes in the expression of cytoskeleton and
sarcomeric proteins
The correct organization and structure of the muscle cytoskel-
eton and sarcomeric proteins are keys to its function and to the
maintenance of its integrity during contraction. This group of
Table 4. Differentially expressed proteins in HIBM versus control muscle biopsies as determined by 2-DE analysis.
Ref.
spot
Description and
gene name
Swiss-Prot
name/ID
HIBM/
Control
Fold
change
Sequence
coverage (%)
Theoretical
Mr (Da)
a)
Theoretical
pI
a)
No. of
confirmatory
MS/MS peptides Possible function
1206 Slow skeletal ventricular
myosin alkali light chain 3
MYL3/P08590 4.95 78 21800.87 5.03 19 Cytoskeleton
organization
3515 Myosin heavy chain
7 cardiac muscle, beta
MYH7/P12883 2.90 25 223733.72 5.60 41 Cytoskeleton
organization
1401 Actin alpha cardiac
muscle precursor
ACTC/P68032 2.01 53 41784.64 5.23 12 Cytoskeleton
organization
1211 Myosin light chain 2 MLRS/Q96A32 1.28 86 18883.38 4.91 13 Cytoskeleton
organization
3511 Vinculin isoform VCL VINC/P18206 1.92 65 123668.11 5.51 63 Cytoskeleton
organization
1401 Tropomyosin 1
alpha chain isoform 1
TPM1/P09493 7.43 87 32708.57 4.69 48 Cytoskeleton
organization
4407 Moesin MOES/P26038 15.27 39 67688.85 6.09 25 Cytoskeleton
organization
7404 Myotilin MYOTI/Q9UBF9 3.92 44 55395.14 9.12 20 Cytoskeleton
organization
4403 Radixin RADI/P35241 1.10 42 68563.90 6.03 23 Cytoskeleton
organization
8204 Troponin I, skeletal, slow TNNI1/P19237 46.12 49 21561.15 9.61 13 Muscle contraction
3305 Troponin T,
slow skeletal muscle
TNNT1/P13805 1.45 36 32816.97 5.86 15 Muscle contraction
7240 Troponin I, skeletal, fast TNNI2/P48788 0.69 58 21207.33 8.88 16 Muscle contraction
2412 Heat shock 70kDa
protein 8 isoform 1
HSP7C/P11142 1.60 61 70766.90 5.37 41 Stress response to
unfolded proteins
3204 Heat shock 27kDa
protein1
HSPB1/P04792 1.49 47 22782.52 5.98 11 Stress response to
unfolded proteins
5208 Crystallin, alpha B CRYAB/P02511 1.22 71 20158.91 6.76 15 Stress response to
unfolded proteins
7401 ATP synthase, H+
transporting, mitochondrial
ATPA/P25705 1.83 51 55209.32 8.28 32 Oxidative
phosphorylation
2408 NADH dehydrogenase
(ubiquinone) Fe-S protein1
NDUS1/P28331 2.26 53 79467.50 5.89 30 Oxidative
phosphorylation
2305 Ubiquinol-cytochrome c
Reductase core protein I
QCR1/P31930 2.20 48 52645.82 5.94 21 Oxidative
phosphorylation
2312 Cytosolic malate
dehydrogenase
MDHC/P40925 0.51 33 36294.93 6.89 10 Carbohydrate
metabolism
5516 Aconitase 2 ACON/Q99798 2.35 40 85425.41 7.36 27 Carbohydrate
metabolism
4505 Oxoglutarate
dehydrogenase isoform
ODO1/Q02218 1.74 44 115935.28 6.39 42 Glycolysis
6409 Pyruvate kinase KPYM/P14618 1.25 73 57805.70 7.95 44 Glycolysis
6513 Phosphofructokinase, muscle K6PF/P08237 3.68 21 85051.33 8.23 14 Glycolysis
5505 Adenosine monophosphate
deaminase 1
AMPD1/P23109 2.20 58 86489.87 6.43 38 Purine metabolism
6208 Prostatic binding protein PEBP1/P30086 4.40 57 20925.59 7.43 9 Signal transduction
in nervous system
5210 Beta globin HBB/P68871 0.60 96 15867.22 6.81 14 Hemoglobin
polymerization
a)Theoretical pI and Mr values were calculated using the ExPASY tool.
doi:10.1371/journal.pone.0016334.t004
The Proteomic Profile of HIBM
PLoS ONE | www.plosone.org 8 January 2011 | Volume 6 | Issue 1 | e16334proteins is highly abundant in muscles and indeed found to be the
major cluster of proteins with altered expression in HIBM by all 3
analyses described here (30%). Similar proteomics studies have
been performed only for few adult onset myopathies. Sporadic
Inclusion Body Myositis (s-IBM), belonging to the inflammatory
group of such diseases and presenting many pathological
similarities with HIBM, was shown to display slightly disturbed
expression patterns of sarcomeric proteins [25] with a switch from
fast to slow twitch type fibers [26] that was previously hypothesized
based on immunohistochemistry data [27]. Proteomic clues of
such a switch were also found in a limb girdle myopathic disorder,
dysferlinopathy [28]. In contrast, our data showed disturbed
cytoskeleton and sarcomeric proteins expression patterns but no
trend was found with regard to the different slow/fast isoforms
expression. Although there is no data describing a different
distribution of slow and fast twitch type fibers in those muscles, it
has to be noted that we have focused on deltoid muscle, whereas
the above mentioned studies examined quadriceps and biceps.
Nevertheless, fast to slow twitch fiber type switch occurs also in
healthy muscle due to disuse [29] or sarcopenia [30–31] and
therefore these parameters should be taken into consideration
when determining whether it is a direct consequence of muscle
disease. Thus, among the myopathies analyzed by proteomics to
date, it could be that changes in the major cluster of cytoskeletal
and sarcomeric proteins are specific to HIBM. These findings raise
the issue of the role of GNE in filament organization and
maintenance. Recently we have shown that GNE interacts with a-
actinin 1, an actin binding protein, at the M line and juxtaposed to
the Z line in mouse muscle [32]. Humans harbor 4 a-actinin
isoforms ,a-actinin 2 and a-actinin 3 are known as muscle proteins
located in the Z-disk and crosslink actin filaments to stabilize the
sarcomere during muscle contraction [33]. Notably, additional
proteins found in this study as differentially expressed in HIBM are
also involved in the sarcomeric organization of muscle fibers:
zyxin, an actinin binding protein was downregulated in HIBM
muscle whereas a-actinin1 precursor and a-actinin 2 are
upregulated, as well as proteins related to calcium binding such
as reticulocalbin 3, reticulocalbin 1 precursor, sarcalumenin and
calsequestrin. Interestingly, calcium related proteins were found to
be downregulated in Duchenne muscular dystrophy where
dystrophin mutations are believed to destabilize the major
sarcolemma dystrophin-glycoprotein complex which in turn affects
sarcolemma integrity and calcium buffering [34,35]. Our results
are in line with the premise that HIBM is not a disorder of the
sarcolemma In addition the hypothesis that GNE plays a role in
the organization of the sarcomere finds further support in the
many features shared by HIBM and tibialis muscular dystrophy
(TMD), a late onset progressive autosomal disease characterized
by weakness in the anterior lower leg (in particular the tibialis
anterior) and rimmed vacuoles. TMD is caused by mutations in
titin, a large protein that serves as an adhesion template for the
assembly of the sarcomere in muscle [22]. Further studies are
required in order to examine the interaction between GNE and
the a-actinin isoforms and to determine whether GNE has a novel
function directly involved in sarcomere filament organization.
Changes in the expression of mitochondrial and
glycolysis proteins
Additional outstanding differentially expressed functional clus-
ters are related to mitochondrial processes such as oxidative
phosphorylation, electron transport and to glycolysis. Clues for
mitochondria functions impairment in HIBM were also found
previously in genomic expression patterns comparison of muscle
specimens from 10 HIBM patients carrying the M712T mutation
and presenting mild histological changes, compared with 10
healthy matched control individuals [24]. A strikingly high
proportion (18.6%) of the overall differentially expressed mRNAs
of known function were found to encode for proteins implicated in
various mitochondrial processes, revealing mitochondria pathways
dysregulation specific to HIBM. Mitochondria are the essential
organelles for energy supply of cells and can respond to multiple
physiological stresses via signaling processes, cell growth and
differentiation events. In particular, they play a major role in cell
death as sensors of apoptotic signals, by releasing various pro-
apoptotic molecules into the cell cytoplasm. The precise events
upstream to mitochondria apoptotic involvement remain to be
fully characterized, however it is well accepted that Akt is a key
factor in this apoptotic/cell survival process. Notably, our previous
findings of a primary impairment of apoptotic events and survival
defects in HIBM cells, as shown by the lack of activated Akt
response to apoptotic stimuli [18], are in line with the mild
mitochondrial alterations described here. To note, in sarcopenia,
mitochondrial activity is enhanced and glycolysis reduced,
probably as a reflection of a more intensive aerobic oxidative
metabolism with age [36], whereas our results point to a more
intense activity of both mitochondrial and glycolysis proteins, thus
probably indicating compensatory effects of the degenerating
mature fiber in HIBM.
Changes in the expression of stress proteins
Inclusion bodies in HIBM have been related to an unfolded
protein response through endoplasmic reticulum and oxidative
stress proteins response mechanisms [37]. Over expression of
ubiquitin and proteosome proteins in HIBM [26] and the recent
identification of similar protein aggregates in an HIBM mouse
model, along with the overexpression of GRP94, support this
hypothesis [38]. In our present analyses of both cultures and
biopsies we found 10 differentially expressed proteins related to
stress response and to the ubiquitin pathway, among them
ANKR2, HSP7C, HSPB1 & CRYAB that are upregulated in
HIBM samples. Increased chaperone expression was also found in
Table 5. Biopsies samples used in the different iTRAQ runs.
Run HIBM Controls Other distal myopathies Internal standard
1 B-147 Del, M (45) B-270 Del, M (48) TMD TA, M (61) B-190 Del, M (32)
2 B-220 TA, F (22) B-181 Del, M (22) MPD3 TA, M (37) B-190 Del, M (32)
3 B-171 Del, F (35) B-190
a) Del, M (32) MPD3 TA, M (44)
WDM TA, F (60)
B-190
a) Del, M (32)
a)In run 3 sample B-190 was used both as control and as internal standard.
Del=Deltoid, TA=Tibialis Anterior, M=Male, F=Female and age of patient (years).
doi:10.1371/journal.pone.0016334.t005
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Description and gene name
Swiss-Prot
name/ID
HIBM/
Control
Fold
change
Sequence
coverage
(%)
Theoretical
Mr (Da)
a)
Theoretical
pI
a)
No. of
confirmatory
MS/MS
peptides Possible function
Myosin light polypeptide 6B MYL6B/P14649 0.53 51 22763.99 5.56 11 Cytoskeleton
organization
Myosin heavy chain 3 MYH3/P11055 0.70 19 223904.73 5.62 3 Cytoskeleton
organization
Myosin heavy chain 2 MYH2/Q9UKX2 3.08 57 223044.46 5.64 68 Cytoskeleton
organization
Myosin light chain 2 MLRS/Q96A32 2.2 88 18883.38 4.91 23 Cytoskeleton
organization
Myosin heavy chain 4 MYH4/Q9Y623 1.63 33 223071.41 5.65 6 Cytoskeleton
organization
Alpha-actinin-2 ACTN2/P35609 1.28 61 103853.79 5.31 62 Cytoskeleton
organization
Tropomyosin alpha-1 chain TPM1/P09493 2.96 54 32708.57 4.62 17 Cytoskeleton
organization
Tropomyosin beta chain TPM2/P07951 1.72 60 32850.73 4.66 19 Cytoskeleton
organization
Myomesin-2 MYOM2/P54296 1.32 15 164896.31 5.82 17 Cytoskeleton
organization
Tubulin beta chain TBB5/P07437 1.49 11 49670.82 4.78 4 Cytoskeleton
organization
Troponin C, skeletal muscle fast TNNC2/P02585 2.06 45 17990.86 4.06 7 Muscle contraction
Troponin I, fast skeletal muscle TNNI2/P48788 2.33 33 21207.33 8.88 12 Muscle contraction
Ankyrin repeat domain-containing
protein 2
ANKR2/Q9GZV1 1.12 23 39859.25 5.72 6 Muscle stress response
Sarcalumenin SRCA/Q86TD4 1.20 8 48692.49 3.81 5 Calcium transport
Protein S100-A4 S10A4/P26447 0.74 27 11597.32 5.88 4 Tubulin Polymerization
Pyruvate kinase isozymes M1/M2 KPYM/P14618 1.58 55 57805.70 7.95 26 Glycolysis
Gamma-enolase ENOG/P09104 1.62 19 47137.39 4.91 1 Glycolysis
Glucose-6-phosphate isomerase G6PI/P06744 1.50 9 63015.93 8.44 5 Glycolysis
Alpha-enolase ENOA/P06733 1.12 24 47037.77 6.99 4 Glycolysis
Triosephosphate isomerase TPIS/P60174 1.38 85 26538.30 6.51 19 Glycolysis
Malate dehydrogenase,
mitochondrial precursor
MDHM/P40926 1.06 29 35503.28 8.92 9 Carbohydrate
metabolism
Malate dehydrogenase,
cytoplasmic
MDHC/P40925 0.91 41 36294.93 6.89 12 Carbohydrate
metabolism
Phosphoglucomutase-1 PGM1/P36871 1.68 23 61317.93 6.32 13 Carbohydrate
metabolism
Glycogen debranching enzyme GDE/P35573 1.64 11 174763.74 6.31 13 Carbohydrate
metabolism
Aldose reductase ALDR/P15121 1.18 16 35722.21 6.55 5 Carbohydrate
metabolism
Glycogen phosphorylase P11217/PYGM 1.78 59 96960.86 6.57 48 Carbohydrate
metabolism
Glyceraldehyde-3-phosphate
dehydrogenase
G3P/P04406 1.42 66 35922.02 8.58 34 Carbohydrate
metabolism
Cytochrome c oxidase subunit 4 COX41/P13073 1.11 24 19576.71 9.52 4 Oxidative
phosphorylation
Calsequestrin-1 CASQ1/P31415 3.31 21 41688.88 3.96 6 Mitochondrial calcium
binding
Dihydrolipoyl dehydrogenase DLDH/P09622 0.85 9 54177.25 7.95 3 Mitochondrial glycine
cleavage
Hydroxyacyl-coenzyme A
dehydrogenase,
HCDH/Q16836 0.87 11 34277.50 8.88 3 Mitochondrial oxidation
Cytochrome b-c1 complex UCRI/P47985 1.37 19 29667.99 8.55 3 Mitochondrial oxidation
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therefore, represent downstream processes common to those
pathologies, such as enhanced functioning of repair mechanisms
to remodel the degenerating fibers. None of the reported
aggregated proteins, tau and beta amyloid in particular, were
detected in our studies; however, this might be due to poor
solubilization.
Proteomic studies on muscle cultures and biopsies from HIBM
specimens, by 2-DE and iTRAQ analyses, emphasize changes in
proteins of the cytoskeleton and the sarcomere filaments, affecting
its maintenance and organization. These findings could point to a
role of GNE in the muscle filamentous apparatus that could
contribute to HIBM pathogenesis.
The altered expression levels of distinct skeletal muscle proteins,
as documented in this study, might be helpful not only for
deepening our understanding of the pathophysiology of HIBM but
also for the future establishment of a comprehensive biomarker
signature of the disease. Reliable markers could be used for
improving diagnostics, monitoring of disease progression and
therapeutic evaluations.
Supporting Information
Figure S1 Functional annotations of the differentially
expressed proteins in HIBM versus controls as analyzed
by 2-DE of muscle cultures.
(TIF)
Figure S2 Western analysis of two matched HIBM/
control muscle culture pairs with antibodies for repre-
sentative proteins.
(TIF)
Description and gene name
Swiss-Prot
name/ID
HIBM/
Control
Fold
change
Sequence
coverage
(%)
Theoretical
Mr (Da)
a)
Theoretical
pI
a)
No. of
confirmatory
MS/MS
peptides Possible function
Peroxiredoxin-6 PRDX6/P30041 1.45 34 24903.79 6.02 7 Redox regulation
Histidine triad nucleotide-binding
protein 1
HINT1/P49773 1.13 51 13670.72 6.46 4 Nucleotide binding
Probable CRU-editing enzyme
APOBEC-2
ABEC2/Q9Y235 1.53 46 25703.14 4.81 7 mRNA editing
Phosphatidylethanolamine-binding
protein 1
PEBP1/P30086 1.27 42 20925.59 7.43 5 Signal transduction in
nervous system
Acyl-CoA-binding protein ACBP/P07108 1.11 20 9913.23 6.11 2 Lipid metabolism
Serum albumin precursor ALBU/P02768 1.49 68 66472.21 5.67 54 Fatty acid & steroid
transport
Glycerol-3-phosphate
dehydrogenase
GPDA/P21695 1.69 20 37436.44 5.82 6 Glycerol metabolism
Alpha-1-antitrypsin precursor A1AT/P01009 0.78 20 46736.55 5.37 7 Protease inhibition
Aspartate aminotransferase,
mitochondrial
AATM/P00505 1.43 25 47475.57 9.14 9 AA metabolism
a)Theoretical pI and Mr values were calculated using the ExPASY tool.
doi:10.1371/journal.pone.0016334.t006
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Figure 3. Functional annotations of the differentially expressed proteins in HIBM versus controls as analyzed by 2-DE of muscle
cultures and 2-DE of biopsies and iTRAQ of biopsies.
doi:10.1371/journal.pone.0016334.g003
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2D gels and iTraq. a–c: HIBM muscle samples; d–f, normal
controls. Arrows point to degenerating fibers with rimmed
vacuoles, showing a similar stage of typical HIBM pathology in
all 3 affected samples; a) tibialis anterior; b–f, deltoid.
(TIF)
Figure S4 Functional annotations of the differentially
expressed proteins in HIBM versus controls as analyzed
by 2-DE of biopsies.
(TIF)
Figure S5 Functional annotations of the differentially
expressed proteins in HIBM versus controls as analyzed
by iTRAQ.
(TIF)
Table S1 MS/MS identification of protein biopsies by
2DE.
(XLS)
Table S2 MS/MS identification of protein biopsies by
iTRAQ.
(XLS)
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